United States: Update On Personal Jurisdiction For BPCIA Litigants After The Supreme Court's Decision In Daimler

Under 35 U.S.C. § 271(e), filing an Abbreviated Biologics License Application (aBLA)—like filing an Abbreviated New Drug Application (ANDA)— can be an act of patent infringement resulting in 'artificial' injury to a patentee.  The artificial nature of the injury challenges traditional understandings of personal jurisdiction.  As Judge Sleet of the District of Delaware put it, in ANDA cases it's "difficult to point to a location out of which the injury 'arises' for jurisdictional purposes...[and] a lawsuit is often inevitable, but it is not clear where it should be held." Astrazeneca AB v. Mylan Pharms, Inc., 72 F. Supp. 3d 549, 558 (D. Del. Nov. 5, 2014).

Prior to the Supreme Court's 2014 decision in Daimler AG v. Bauman, 134 S. Ct. 746 (2014) (discussed in detail in an earlier post), plaintiffs in ANDA cases regularly relied on concepts of general jurisdiction to bring suit against corporations in any state for products sold nationally.  However, since Daimler effectively limits general jurisdiction over corporations to their "home" state—their state of incorporation or principal place of business—plaintiffs in ANDA cases have faced a slew of motions to dismiss for lack of personal jurisdiction over defendants outside their home states. Id. at 760.

In post-Daimler ANDA cases, patentees have relied on two theories of personal jurisdiction.  The first theory involves consent jurisdiction, i.e., that a defendant who registers to do business in a state has consented to general jurisdiction there.  The second theory involves specific jurisdiction, i.e., that a defendant who files an ANDA and a paragraph IV certification directs its activities at the plaintiff in its home forum, and the harm of that filing is felt by the plaintiff there.

Both theories are at play in Mylan's interlocutory appeal to the Federal Circuit of the district court's decisions in Astrazeneca AB v. Mylan Pharms, Inc., 72 F. Supp. 3d 549, 558 (D. Del. Nov. 5, 2014)., Fed. Cir. Docket No. 15-1460 and in Acorda Therapeutics v. Mylan Pharms. Inc., 78 F. Supp. 3d 572 (D. Del. Jan. 14, 2015), Fed. Cir. Docket No. 15-1456. Briefing is complete, and the cases are likely to be argued before the Federal Circuit early in 2016.

While the appeal is pending, decisions by district courts in Delaware, New Jersey, the Eastern District of Texas, and the Southern District of Indiana have addressed these issues. The table below summarizes the courts' findings on personal jurisdiction in twelve recent ANDA cases.

  General "at home" Jurisdiction Consent Jurisdiction Specific Jurisdiction
Astrazeneca AB v. Mylan Pharms., Inc., 72 F. Supp. 3d 549 (D. Del. Nov. 5, 2014). No No Yes
Allergan Inc. v. Actavis Inc., 14-CV-638, 2014 U.S. Dist. LEXIS 176551 (E.D.Tex. Dec. 23, 2014) N/A N/A Yes
Acorda Therapeutics v. Mylan Pharms. Inc., 78 F. Supp. 3d 572 (D. Del. Jan. 14, 2015). No Yes Yes
Forest Labs, Inc. v. Amneal Pharms, LLC, No. 14-508, 2015 U.S. LEXIS 23215 (D. Del. Feb. 26, 2015) N/A Yes N/A
Eli Lilly v. Mylan Pharms., Inc., No. 14-cv-00389, 2015 U.S. Dist. LEXIS 30175 (S.D. Ind. Mar. 12, 2015) No N/A Yes
Novartis Pharms. Corp. v. Mylan Inc., No. 14-777, 2015 U.S. Dist. LEXIS 31812 (D. Del. March 16, 2015) No Yes Granted discovery
Otsuka Pharm. Co. v. Mylan Inc. No. 14-4508, 2015 U.S. Dist. LEXIS 35679 (D.N.J. March 23, 2015) N/A Yes Granted discovery
Senju Pharm. Co. v. Metrics, Inc., No. 14-3962, 2015 U.S. Dist. LEXIS 41504 (D.N.J. March 31, 2015) No Yes Granted discovery
Janssen Products, L.P. et al. v. Mylan Pharms. Inc. et al., No. 14-4550-WHW-CLW (D.N.J. July 8, 2015) N/A Yes N/A
Boehringer Ingelheim Pharma GmbH v. Teva Pharms. USA, Inc., 2015 U.S. Dist. LEXIS 92921, *6 (D.N.J. July 16, 2015) N/A Yes N/A
Purdue v. Collegium Pharm., 2015 U.S. Dist. LEXIS 102899 (D. Del. Aug. 6, 2015) No N/A No
Novartis v. Zydus Noveltech, No. 14-cv-1104-RGA, 2015 U.S. Dist. LEXIS 103708 (D. Del. August 7, 2015) No N/A No
Eli Lilly & Co. v. Nang Kuang Pharm. Co., 2015 U.S. Dist. LEXIS 111510, (S.D. Ind. Aug. 24, 2015) 1:14-cv-01647-TWP-DKL N/A N/A Yes

Of the post-Daimler district courts that have considered consent to jurisdiction by registration in ANDA cases, only Judge Sleet in Astrazeneca rejected the theory.

As for specific jurisdiction, in none of these cases was the specific jurisdiction theory rejected.  Judge Sleet, in Astrazeneca, concluded that the defendants had established minimum contacts with the plaintiff's home forum by sending a paragraph IV notice letter to plaintiffs in Delaware, and could reasonably anticipate being haled into the forum to which the paragraph IV letter was sent.  This begs the question—if the defendant had sent the paragraph IV notice letter to one of the plaintiff's subsidiaries or to the plaintiff at a different location, could the plaintiff still sue the defendant in its home forum?

In Acorda Therapeutics v. Mylan Pharms. Inc., Judge Stark concluded that mailing a paragraph IV notice letter into the forum was not a prerequisite for finding specific jurisdiction in that forum. 78 F. Supp. 3d 572 (D. Del. Jan. 14, 2015).  Judge Stark recognized that the plaintiff, a Delaware corporation, was injured in Delaware by the ANDA filing and that it was fair to exercise personal jurisdiction in Delaware given defendants' other contacts with the forum including registration to do business, registration with the Board of Pharmacy, and litigation history in Delaware.

Only two district court decisions, both in Delaware, granted a defendant's motion to dismiss for lack of personal jurisdiction: Purdue v. Collegium Pharm., 2015 U.S. Dist. LEXIS 102899 (D. Del. Aug. 6, 2015) and Novartis Pharms. Corp. v. Zydus Noveltech, Inc. 2015 U.S. Dist. LEXIS 103708 (D. Del. Aug. 7, 2015).  In both cases, defendants were not registered to do business in Delaware, and defendants had not sent a paragraph IV certification into Delaware.  In Purdue, Judge Robinson found that defendants had not sent a paragraph IV notice letter to Delaware, and that the defendants had no additional contacts with the forum—no business registration, no preparation of the ANDA, no research or relevant manufacturing.  Id. at *13-14. Similarly, in Novartis Pharms. Corp. v. Zydus Noveltech, Inc., Judge Andrews concluded that asserting personal jurisdiction over Defendants for sending a paragraph IV notice letter to a Delaware corporation in New Jersey would not pass constitutional muster absent any other contacts with the forum. Judge Andrews agreed with Judge Stark that mailing a paragraph IV notice letter into the forum was not a prerequisite to finding specific jurisdiction in that forum, but found that defendants had no additional contacts with the forum. Id. at *12.  Defendants were not registered to do business in Delaware, had never litigated a case in Delaware in any context, had no property or staff in Delaware, and in fact conducted no business in the forum at all. Id.

Under these cases, plaintiffs in ANDA and BPCIA cases will continue to rely on both theories of personal jurisdiction.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions